Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bill Wexler's Profits of DOOM -- Ignore unavailable to you. Want to Upgrade?

To: Bill Wexler who wrote (14)	2/20/1998 5:39:00 PM
From: Jim Roof	Read Replies (1) \| Respond to of 4634

Bill, You used the word 'scam' four times in your post and again choose to simply tell me that my claims are wrong in such non-specific ways. You have again exemplified my beef with your 'analysis'. I present specific empirical data and then you say something like "the data does NOT show that Hextend is superior". That just don't cut it. Please tell me precisely how the studies were faked? That rumor has been around for months yet no one has stated anything specific and I doubt you can either. Please tell me why the insiders have chosen to ride out the decline from 27 to 12 rather than liquidate at least a portion of their shares on the backs of the severely scammed? As for the use of leverage, you are right, but what issues are they buying with the use of their BTIM stock as collateral? More BTIM stock! As far as my interpretation of the phase III data I am absolutely on the money with it. The Hextend group had lower platelet counts as well as lower hemoglobin. At first glance one would assume that this is a strong negative because we need platelets to clot and hemoglobin to oxygenate but there is a very powerful hidden positive tidbit hidden from your eyes here. That is the fact that these patients had these lower numbers because their systems better tolerated higher levels of the expander than did the hespan/hetastarch group. Ie., Hextend patients did not need to receive as much transfused blood or platelets during and after their surgery. Their blood clotted fine with less platelets and Hextend than did the hespan patients with MORE platelets. This shows clear superiority for Hextend over Hespan. Any claim to the contrary is simply an unsupported opinion or is patently dishonest. Jim